CA2160877A1 - Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables - Google Patents

Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables

Info

Publication number
CA2160877A1
CA2160877A1 CA 2160877 CA2160877A CA2160877A1 CA 2160877 A1 CA2160877 A1 CA 2160877A1 CA 2160877 CA2160877 CA 2160877 CA 2160877 A CA2160877 A CA 2160877A CA 2160877 A1 CA2160877 A1 CA 2160877A1
Authority
CA
Canada
Prior art keywords
antisense
microparticle
oligodeoxyribonucleotide
lactic acid
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2160877
Other languages
English (en)
Inventor
Michael David Amos
Sandra Gertrude Mcelligott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
MEDISORB TECHNOLOGIES INTERNATIONAL LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDISORB TECHNOLOGIES INTERNATIONAL LP filed Critical MEDISORB TECHNOLOGIES INTERNATIONAL LP
Publication of CA2160877A1 publication Critical patent/CA2160877A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA 2160877 1993-04-19 1994-04-19 Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables Abandoned CA2160877A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4767293A 1993-04-19 1993-04-19
US08/047,672 1993-04-19

Publications (1)

Publication Number Publication Date
CA2160877A1 true CA2160877A1 (fr) 1994-10-27

Family

ID=21950303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2160877 Abandoned CA2160877A1 (fr) 1993-04-19 1994-04-19 Traitement prolonge grace a la liberation-retard d'oligodesoxyribonucleotides antisens a partir de microparticules biodegradables

Country Status (6)

Country Link
EP (1) EP0695170A4 (fr)
JP (1) JPH08511418A (fr)
AU (1) AU6637394A (fr)
CA (1) CA2160877A1 (fr)
NZ (1) NZ265555A (fr)
WO (1) WO1994023699A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
EP0844004B1 (fr) * 1995-07-03 2007-09-12 Koken Co., Ltd. Preparations de genes contenant d' atelocollagene
EP0840623B1 (fr) 1995-07-21 2007-07-18 Brown University Research Foundation Compositions pour la thérapie génétique contenant des microparticules polymères chargées d'un acide nucléique
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
CA2241835A1 (fr) * 1995-10-19 1997-04-24 Cordis Corporation Conjugaison d'oligonucleotides anti-sens c-myc avec le cholesterol pour renforcer de maniere importante leur effet inhibiteur sur l'hyperplasie de la neo-intima
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
WO1997017063A1 (fr) 1995-11-09 1997-05-15 Microbiological Research Authority Adn microencapsule s'appliquant dans des procedes de vaccination et de therapie genique
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
DK1005374T3 (da) * 1997-01-22 2007-08-20 Mgi Pharma Biolog Inc Mikropartikler til fremföring af nukleinsyre
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
EP1096957A1 (fr) 1998-06-18 2001-05-09 Johns Hopkins University School of Medicine Methodes et reactifs d'administration intramusculaire d'acides nucleiques
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU3323902A (en) * 2000-12-13 2002-06-24 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
JP6367196B2 (ja) 2012-08-14 2018-08-01 テンエックス・ジェノミクス・インコーポレイテッド マイクロカプセル組成物および方法
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN104981236B (zh) * 2012-09-27 2019-01-22 珠海圣美生物诊断技术有限公司 刺激敏感性微粒和使用方法
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP3567116A1 (fr) 2012-12-14 2019-11-13 10X Genomics, Inc. Procédés et systèmes de traitement de polynucléotides
KR102190198B1 (ko) 2013-02-08 2020-12-14 10엑스 제노믹스, 인크. 폴리뉴클레오티드 바코드 생성
CA2943624A1 (fr) 2014-04-10 2015-10-15 10X Genomics, Inc. Dispositifs fluidiques, systemes et procedes permettant d'encapsuler et de separer des reactifs, et leurs applications
EP4574974A3 (fr) 2014-06-26 2025-10-08 10x Genomics, Inc. Procédés d'analyse d'acides nucléiques à partir de cellules individuelles ou de populations cellulaires
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
WO2015200869A1 (fr) 2014-06-26 2015-12-30 10X Genomics, Inc. Analyse de séquences d'acides nucléiques
WO2016069939A1 (fr) 2014-10-29 2016-05-06 10X Genomics, Inc. Procédés et compositions de séquençage ciblé d'acides nucléiques
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
CN107427808B (zh) 2015-01-12 2020-10-23 10X基因组学有限公司 用于制备核酸测序文库的方法和系统以及用其制备的文库
CN107532202A (zh) 2015-02-24 2018-01-02 10X 基因组学有限公司 用于靶向核酸序列覆盖的方法
EP3262407B1 (fr) 2015-02-24 2023-08-30 10X Genomics, Inc. Procédés et systèmes de traitement de cloisonnement
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
WO2017070056A1 (fr) * 2015-10-20 2017-04-27 10X Genomics, Inc. Procédés et systèmes de manipulation génétique sur cellules isolées à haut débit
SG10202108763UA (en) 2015-12-04 2021-09-29 10X Genomics Inc Methods and compositions for nucleic acid analysis
WO2017147240A1 (fr) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Conjugués et particules ciblant hsp90 et leurs formulations
WO2017197343A2 (fr) 2016-05-12 2017-11-16 10X Genomics, Inc. Filtres microfluidiques sur puce
WO2017197338A1 (fr) 2016-05-13 2017-11-16 10X Genomics, Inc. Systèmes microfluidiques et procédés d'utilisation
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP4310183B1 (fr) 2017-01-30 2025-07-09 10X Genomics, Inc. Procédés et systèmes de codage à barres de cellules uniques à base de gouttelettes
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
CN109526228B (zh) 2017-05-26 2022-11-25 10X基因组学有限公司 转座酶可接近性染色质的单细胞分析
CN111051523B (zh) 2017-11-15 2024-03-19 10X基因组学有限公司 功能化凝胶珠
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
WO2019195166A1 (fr) 2018-04-06 2019-10-10 10X Genomics, Inc. Systèmes et procédés de contrôle de qualité dans un traitement de cellules uniques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4919929A (en) * 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0248531A3 (fr) * 1986-05-02 1988-09-28 Southern Research Institute Acides nucléiques encapsulés
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy

Also Published As

Publication number Publication date
AU6637394A (en) 1994-11-08
JPH08511418A (ja) 1996-12-03
NZ265555A (en) 1997-09-22
WO1994023699A1 (fr) 1994-10-27
EP0695170A4 (fr) 1998-08-19
EP0695170A1 (fr) 1996-02-07

Similar Documents

Publication Publication Date Title
AU6637394A (en) Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
US6555525B2 (en) Microencapsulation and sustained release of oligonucleotides
EP2072040B1 (fr) L'emploi thérapeutique des microsphères d'acide nucléique
EP0696200A1 (fr) Encapsulation d'acides nucleiques avec des conjugues qui facilitent et ciblent l'absorption cellulaire et l'expression genique
US9115357B2 (en) Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
AU2121495A (en) Polymeric gene delivery system
Lewis et al. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P (LA-GA) copolymer microspheres in vitro
Lewis et al. Biodegradable poly (L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides
Zon Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications: Prospects for neurobiology
Khan et al. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain
CN1980640A (zh) 核酸微球体，其制备和递送
Lewis Biodegradable polymers for the sustained release of antisense nucleic acids
Smith CNS delivery of antisense oligodeoxynucleotides using biodegradable microspheres
Ricci et al. New approaches for the delivery of oligonucleotides (ODNs)
Woodle et al. Liposomal antisense oligonucleotide therapeutics
Koo et al. Cellular effects of antisense c-myc oligodeoxynucleotides are delivery dependent
Raman Computational and experimental studies of controlled release drug delivery: Effect of microsphere diameter and drug size on in-vitro release kinetics
Arias Mediano Novel Strategies to Improve the Anticancer Action of 5-Fluorouracil by Using Drug Delivery Systems

Legal Events

Date Code Title Description
FZDE Discontinued